Clinical trials: Prostate Neoplasm
Prostate Cancer
Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation
French epidemiological data have shown a heterogeneous distribution of the risk of mortality from prostate cancer according to region.
- Trial name
- FACT (NCT01729676)
- Testing
- Degarelix or GnRH agonist
- Where
- France
- Volunteers
- 315 people
- Sponsor
- Ferring Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer
To evaluate whether the efficacy of the abiraterone acetate tablets (I) is comparable to that of the ZYTIGA®) by comparing the serum testosterone concentrations on Day 9 and/or Day 10 after oral administration of the two…
- Trial name
- NCT04862091
- Testing
- Abiraterone Acetate Tablets (I), ZYTIGA®
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])
This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 Diagnostic Performance Period.
- Trial name
- SPARROW (NCT07831824)
- Testing
- [68Ga]-LNTH-2401
- Where
- United States
- Volunteers
- 408 people
- Sponsor
- Lantheus Medical Imaging
Prostatic Neoplasms
Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy
This is a prospective, multicenter, open-label, randomized phase III study in participants at high risk of recurrent prostate cancer after radical prostatectomy.
- Trial name
- NCT00283062
- Testing
- Docetaxel (TAXOTERE®) Chemotherapy, Leuprolide acetate ( ELIGARD®) Hormonal Therapy
- Where
- 17 sites in United States, Australia and 15 more
- Volunteers
- 228 people
- Sponsor
- Sanofi
Prostatic Cancer, Castration-Resistant
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617)…
- Trial name
- NCT07047118
- Testing
- JSB462, AAA617
- Where
- 44 sites in United States, Australia and 13 more
- Volunteers
- 138 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
The purpose of this trial is to confirm a safe dose of AS1404, to be given with docetaxel, and to see whether adding AS1404 and docetaxel together improves the outcome of the treatment, when compared to docetaxel alone.
- Trial name
- NCT00111618
- Testing
- AS1404 (DMXAA)
- Where
- 27 sites in United States
- Volunteers
- 70 people
- Sponsor
- Antisoma Research
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Prostatic Neoplasms
Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2
The monoclonal antibody J591 is being investigated as therapy for patients with prostate cancer, in combination with recombinant interleukin-2 (Proleukin, Aldesleukin).
- Trial name
- NCT00040586
- Testing
- Monoclonal Antibody J591, Recombinant Interleukin-2
- Where
- United States
- Sponsor
- BZL Biologics
Prostate Cancer
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
This is a Phase I, multicenter, open-label, dose-escalation study of DSTP3086S administered as a single agent by intravenous (IV) infusion to patients with metastatic Castration-Resistant Prostate Cancer (CRPC).
- Trial name
- NCT01283373
- Testing
- DSTP3086S
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- Genentech, Inc.
Prostate Cancer
Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer
The purpose of this trial is to evaluate a short course of very focused (stereotactic) external beam radiation therapy for the treatment of early stage prostate cancer.
- Trial name
- NCT00969202
- Testing
- Stereotactic Radiosurgery using the Novalis Tx
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- San Diego Radiosurgery
Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy Failure
Study of Photodynamic Therapy in Patients With Prostate Cancer Following Radiation Therapy
To assess by MR Imaging the lesions induced by WST09-mediated photodynamic therapy (PDT) in patients with recurrent or persistent localized prostate cancer following definitive radiotherapy using different light doses and…
- Trial name
- NCT00308919
- Testing
- WST09
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- STEBA France
High Risk Localized Prostate Cancer
A Study of High Risk Localized Prostate Cancer Participants Treated With Radical Prostatectomy and Perioperative Hormonal Therapy
The purpose of this study is to evaluate the yearly conditional prostate-specific antigen (PSA) progression-free survival (PFS) probabilities in high-risk localized prostate cancer (HR LPC) participants following radical…
- Trial name
- ACE (NCT05303558)
- Where
- 9 sites in Japan, South Korea and 1 more
- Volunteers
- 221 people
- Sponsor
- Johnson & Johnson International (Singapore) Pte. Ltd.
Prostate Cancer
Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body
Study to gather information about the optimal placement of Ra-223 in the order of different treatments in terms of the effect on patients and in terms of the use of healthcare services for the treatment of Canadian patients with…
- Trial name
- REACTIVATE (NCT04281147)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- Canada
- Volunteers
- 4,301 people
- Sponsor
- Bayer
Prostate Cancer, 18F- Fluorocholine
Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7
The present study in patients with Prostate cancer and biochemical failure after surgery and/or radical-postoperative Radio Therapy (RT) will evaluate if PET/CT with 18F-JK-PSMA-7 compared to PET-CT 18F-Choline is able to…
- Conditions
- Prostate Cancer, 18F- Fluorocholine, PSMA PET, Radiotherapy
- Trial name
- MIP7 (NCT05622162)
- Testing
- Radiopharmaceutical 18F-JK-PSMA-7, Radiopharmaceutical 18F-Fluorocholine
- Where
- 2 sites in Italy
- Volunteers
- 106 people
- Sponsor
- ITEL Telecomunicazioni Srl
Breast Cancer, Pancreas Cancer
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
- Conditions
- Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer
- Trial name
- NCT03199586
- Testing
- NP-G2-044
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Novita Pharmaceuticals, Inc.
Prostate Cancer
PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer
This Phase 1 trial will evaluate the safety and tolerability of PSA-Activated PSA-PAH1 in subjects who have shown biochemical failure and have either completed at least one primary radiation therapy for prostate cancer and have…
- Trial name
- NCT00379561
- Testing
- PSA-Activated PSA-PAH1
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sophiris Bio Corp
Metastatic Prostate Cancer
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
This is a randomized, open-label study designed to assess the effects of sipuleucel-T when administered concurrently or sequentially with enzalutamide.
- Trial name
- NCT01981122
- Testing
- sipuleucel-T, enzalutamide
- Where
- 19 sites in United States
- Volunteers
- 52 people
- Sponsor
- Dendreon
Prostate Cancer
Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of Lutetium Lu 177 JH020002 Injection in adult patients with advanced prostate cancer.
- Trial name
- NCT06139575
- Testing
- Lutetium Lu 177 JH020002 Injection
- Where
- 13 sites in China
- Volunteers
- 90 people
- Sponsor
- Bivision Pharmaceuticals, Inc.
Prostate Cancer
IS-002 Phase 2 Prostate Cancer Study
Phase 2 randomized controlled multi-center study of IS-002, in conjunction with near-infrared (NIR) fluorescence imaging, for identification of prostate cancer during robotic-assisted radical prostatectomy (RARP) with (extended)…
- Trial name
- NCT05946603
- Testing
- Administration of IS-002, Firefly fluorescent imaging, robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Intuitive Surgical
Prostate Cancer
Open Label Trial to Assess Iressa in Prostate Cancer Patients
A study to assess the activity of Iressa in patients who's prostate cancer has recurred, and who have rising PSA levels
- Trial name
- NCT00635856
- Testing
- Gefitinib
- Volunteers
- 100 people
- Sponsor
- AstraZeneca